BPA Biosante Pharmaceuticals

NEW YORK, July 10 /PRNewswire/ -- On June 19, Stephen Simes, CEO of Biosante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics: -- the company's "wide portfolio" of hormone therapy products -- size of the company's target markets, and market opportunities for the company's gel formulations -- hormone therapy products in development -- reasons the company's transdermal products have a competitive edge -- upcoming milestones for investors to watch for To hear the interview in its entirety, and to read an in-depth report on the company, visit http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=bpa On June 29, Jennifer Good, President CEO of Penwest Pharmaceuticals Co. (NASDAQ:PPCO) (http://www.penw.com/) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics: -- reasons the company is going through a "bit of a transition" -- why Opana ER "has a lot of earnings leverage for Penwest" -- the company's relationship with Endo Pharmaceuticals, Inc. -- the company's three-pronged strategy to build its pipeline -- building a specialty sales force in neurology -- industry trends bolstering the company's growth prospects -- upcoming milestones for investors to watch for To hear the interview in its entirety, visit http://www.wallst.net/audio/audio.asp?ticker=PPCO&id=3565 On June 20, Dr. Rahul Singhvi, President and CEO of Novavax, Inc. (NASDAQ:NVAX) (http://www.novavax.com/ ) updated the investment community in an all-new interview with http://www.wallst.net/. Interview highlights include detailed discussions on the following topics: -- reasons the company is "very well positioned to be a major vaccine player" -- commercial opportunities for the company's virus-like-particle approach to vaccine development -- initial targets for vaccine development -- development of the company's Avian Flu vaccine candidate -- proven track record of virus-like-particle-based drugs -- upcoming development milestones for investors to watch for To hear the interview in its entirety, and to read an in-depth article on the company, visit http://www.wallst.net/editorials/article.asp?id=731 About WallSt.net: http://www.wallst.net/ is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com/). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net/, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com/), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com/), a business and finance podcast Web site. We have received nine thousand nine hundred ninety five dollars from Biosante Pharmaceuticals, Inc. for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp . (Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO) http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO http://photoarchive.ap.org/ DATASOURCE: WallStreet Direct, Inc. CONTACT: Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALLST Web site: http://www.biosantepharma.com/ http://www.wallst.net/ http://www.penw.com/ http://www.novavax.com/

Copyright